诺辉健康 New Horizon Health Limited

诺辉健康 New Horizon Health Limited is a pioneering company in China’s cancer screening market, with a vision to prevent and cure cancer through early detection and screening. Founded in 2015, the company has made significant strides in this direction. New Horizon Health has two commercialized medical tests for colorectal cancer screening and two late-stage pipeline candidates for gastric and cervical cancer screening, holding global rights to all its products. The company's flagship product, ColoClear, is a home-based, non-invasive FIT-DNA test that targets 120 million colorectal high-risk population in China. It is the first and only cancer screening test approved by the NMPA. Additionally, Pupu Tube, the first self-conducted FIT screening test targeting 630 million population to identify colorectal high-risk individuals in China, has also received NMPA approval and obtained the CE Mark. New Horizon Health has several strengths that set it apart in the industry, such as being the only player with NMPA-approved products in China’s cancer screening market and having a focused and synergistic cancer screening portfolio. Its strategic partnerships with healthcare investors further strengthen its positioning in the market. The company's strategies include developing the cancer screening market in China and increasing the market penetration of its flagship products. The most recent round of funding, a $30.00M Series E investment led by a consortium of prolific investors including Lilly Asia Ventures, Qiming Venture Partners, OrbiMed, Cormorant Asset Management, Octagon Capital Advisors, Rock Springs Capital, and CR-CP Life Science Fund in July 10, 2020, is indicative of strong investor confidence in New Horizon Health's potential. With its pioneering approach and strong market positioning, New Horizon Health is poised to make significant strides in the field of cancer screening and early detection.